Summary
Quest Diagnostics Inc. reported strong performance for the nine months ended September 30, 2015, with net income attributable to Quest Diagnostics shareholders increasing by 42.5% to $521 million, and diluted EPS growing to $3.58 from $2.51 in the prior year period. This significant growth was largely driven by a substantial pre-tax gain of $334 million from the contribution of its clinical trials testing business to a joint venture. Excluding this one-time gain, the company demonstrated solid operational execution, with stable revenues in its core Diagnostic Information Services (DIS) segment and effective cost management through its Invigorate program, which is on track to achieve significant run-rate savings. Financially, the company managed its debt effectively, completing a $1.2 billion senior notes offering and using proceeds to retire higher-interest debt, though this resulted in a $144 million loss on debt retirement for the nine-month period. The company also continued its commitment to shareholder returns through dividends and share repurchases. While facing some revenue headwinds in its Diagnostic Solutions (DS) segment due to the joint venture contribution, the overall financial health and operational efficiency improvements position Quest Diagnostics favorably.
Financial Highlights
57 data points| Revenue | $1.88B |
| Cost of Revenue | $1.16B |
| Gross Profit | $718.00M |
| SG&A Expenses | $402.00M |
| Operating Expenses | $1.25B |
| Operating Income | $631.00M |
| Interest Expense | $35.00M |
| Net Income | $342.00M |
| EPS (Basic) | $2.37 |
| EPS (Diluted) | $2.35 |
| Shares Outstanding (Basic) | 144.00M |
| Shares Outstanding (Diluted) | 145.00M |
Key Highlights
- 1Net income attributable to Quest Diagnostics shareholders increased by 42.5% to $521 million for the nine months ended September 30, 2015, compared to $366 million in the prior year.
- 2Diluted earnings per share (EPS) rose to $3.58 for the nine months ended September 30, 2015, up from $2.51 in the same period last year, significantly boosted by a $334 million pre-tax gain from a joint venture contribution.
- 3Total net revenues for the nine months increased by 1.7% to $5,644 million, driven by acquisitions and growth in the core DIS segment.
- 4The company continues to execute its 'Invigorate' cost-saving program, aiming for $1.3 billion in total run-rate savings by the end of 2017.
- 5Quest Diagnostics completed a $1.2 billion senior notes offering in March 2015, with proceeds used to retire higher-interest debt, incurring a $144 million loss on early debt retirement.
- 6Cash provided by operating activities for the nine months was $539 million, although this was lower than the prior year due to debt retirement costs and tax payments.
- 7The company maintained its commitment to shareholders, increasing quarterly dividends to $0.38 per share and actively repurchasing shares, with $522 million remaining under existing authorizations.